www.fdanews.com/articles/197547-astrazeneca-licenses-vanderbilt-universitys-monoclonal-antibodies-for-covid-19
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19
June 10, 2020
AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19.
Monoclonal antibodies are synthesized versions of natural antibodies that may be able to neutralize the SARS-CoV-2 virus.
The company said it plans to begin a study of two antibodies as a combination treatment within the next two months.